WO2001091733A3 - Combination of active substances containing montirelin and a compound having an opioid effect - Google Patents

Combination of active substances containing montirelin and a compound having an opioid effect Download PDF

Info

Publication number
WO2001091733A3
WO2001091733A3 PCT/EP2001/005345 EP0105345W WO0191733A3 WO 2001091733 A3 WO2001091733 A3 WO 2001091733A3 EP 0105345 W EP0105345 W EP 0105345W WO 0191733 A3 WO0191733 A3 WO 0191733A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
active substances
montirelin
compound
substances containing
Prior art date
Application number
PCT/EP2001/005345
Other languages
German (de)
French (fr)
Other versions
WO2001091733A2 (en
Inventor
Boris Chizh
Thomas Christoph
Babette-Yvonne Koegel
Achim Schuettler
Wolfgang Strassburger
Original Assignee
Gruenenthal Gmbh
Boris Chizh
Thomas Christoph
Koegel Babette Yvonne
Achim Schuettler
Wolfgang Strassburger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh, Boris Chizh, Thomas Christoph, Koegel Babette Yvonne, Achim Schuettler, Wolfgang Strassburger filed Critical Gruenenthal Gmbh
Priority to AU2001274020A priority Critical patent/AU2001274020A1/en
Publication of WO2001091733A2 publication Critical patent/WO2001091733A2/en
Publication of WO2001091733A3 publication Critical patent/WO2001091733A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a combination of active substances containing montirelin and a compound having an opioid effect and/or respectively the physiologically compatible salts thereof; a medicament containing said combination of active substances; formulations for medicaments containing said combination of active substances; the use of said combination of active substances in the production of a medicament.
PCT/EP2001/005345 2000-05-26 2001-05-10 Combination of active substances containing montirelin and a compound having an opioid effect WO2001091733A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001274020A AU2001274020A1 (en) 2000-05-26 2001-05-10 Combination of active substances containing montirelin and compound having an opioid effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10025947A DE10025947A1 (en) 2000-05-26 2000-05-26 Active ingredient combination containing montirelin and a compound with opioid activity
DE10025947.2 2000-05-26

Publications (2)

Publication Number Publication Date
WO2001091733A2 WO2001091733A2 (en) 2001-12-06
WO2001091733A3 true WO2001091733A3 (en) 2002-04-04

Family

ID=7643551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005345 WO2001091733A2 (en) 2000-05-26 2001-05-10 Combination of active substances containing montirelin and a compound having an opioid effect

Country Status (5)

Country Link
AR (1) AR029096A1 (en)
AU (1) AU2001274020A1 (en)
DE (1) DE10025947A1 (en)
PE (1) PE20011272A1 (en)
WO (1) WO2001091733A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
CN102770127B (en) * 2010-02-24 2015-04-15 思玛化验室公司 Abuse-resistant formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BHARGAVA HEMENDRA N ET AL: "Effect of thyrotropin releasing hormone on U-50,488H-induced pharmacological responses in mice.", BRAIN RESEARCH, vol. 625, no. 1, 1993, pages 120 - 124, XP001029522, ISSN: 0006-8993 *
ITOH YOSHINORI ET AL: "Enhancement of brain noradrenaline and dopamine turnover by thyrotropin-releasing hormone and its analogue NS-3 in mice and rats.", PHARMACOLOGY & TOXICOLOGY, vol. 78, no. 6, 1996, pages 421 - 428, XP001029649, ISSN: 0901-9928 *
UKAI YOJIRO ET AL: "Effects of montirelin hydrate (NS-3), a TRH analog, on the cerebral glucose utilization and high affinity choline uptake in rats.", OYO YAKURI, vol. 51, no. 3, 1996, pages 147 - 153, XP001022252, ISSN: 0300-8533 *
WANG G-L ET AL: "EFFECTS OF THYROTROPIN-RELEASING HORMONE ON ACUTE EXPERIMENTAL TRAUMATIC HEAD INJURY IN CATS", CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 104, no. 11, 1991, pages 939 - 944, XP001022253, ISSN: 0366-6999 *
YAMAMOTO M ET AL: "EFFECTS OF YM-14673 A NEW TRH ANALOGUE ON RESPONSES TO MORPHINE IN RODENTS", ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, vol. 300, 1989, pages 29 - 36, XP001029545, ISSN: 0003-9780 *
ZHUKOV V N ET AL: "HYPERTHERMIA AND ANTINOCICEPTIVE ACTIVITY OF TRH AND MORPHINE FOLLOWING CENTRAL ADMINISTRATION IN RATS", ACTA PHYSIOLOGICA ET PHARMACOLOGICA BULGARICA, vol. 14, no. 2, 1988, pages 18 - 23, XP001022256, ISSN: 0323-9950 *

Also Published As

Publication number Publication date
AU2001274020A1 (en) 2001-12-11
PE20011272A1 (en) 2002-01-26
DE10025947A1 (en) 2001-11-29
WO2001091733A2 (en) 2001-12-06
AR029096A1 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
EP1246608A4 (en) Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
IL149186A0 (en) Pharmaceutical compositions providing enhanced drug concentrations
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
MXPA03007712A (en) Pharmaceutical salts.
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
MXPA03004941A (en) Drug formulation having improved oral tolerability.
AU2002227910A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
AU2001234114A1 (en) Drugs containing combined active ingredients
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
WO2002015959A3 (en) Compounds and compositions for delivering active agents
PL346764A1 (en) New oral formulation for 5-ht4
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU2001291731A1 (en) Pharmaceutical, effervescent formulation containing ramipril
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
WO2001091733A3 (en) Combination of active substances containing montirelin and a compound having an opioid effect
GEP20043377B (en) Pharmaceutical Complex
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP